NCT02077192

Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 123 (actual)
• Sponsor: Rigel Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study was to assess the long term safety of fostamatinib in subjects with persistent/chronic ITP

Conditions

• Immune Thrombocytopenic Purpura

Interventions

Type	Name	Description
DRUG	Fostamatinib Disodium	Fostamatinib Disodium tablet 100 mg or 150 mg by mouth twice a day

Timeline

• Start date: 2014-10-01
• Primary completion: 2020-06-02
• Completion: 2020-06-02
• First posted: 2014-03-04
• Last updated: 2023-12-11
• Results posted: 2023-12-11

Locations

55 sites across 15 countries: United States, Australia, Austria, Bulgaria, Canada, Czechia, Denmark, Hungary, Italy, Netherlands, Norway, Poland, Romania, Spain, United Kingdom